Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Targets. 2008 May;12(5):589-603. doi: 10.1517/14728222.12.5.589 .

Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer.

Author information

1
Weatherall Institute of Molecular Medicine, University of Oxford, IGF Group, Molecular Oncology Laboratories, Headley Way, Headington, Oxford OX3 9DS, UK.

Abstract

BACKGROUND:

The type 1 insulin-like growth factor receptor (IGF1R) plays a critical role in transformation, invasion and apoptosis protection, and is an attractive cancer treatment target.

OBJECTIVE:

To review IGF1R antibodies and kinase inhibitors that are in preclinical and clinical development, and to discuss questions that will influence the success of this approach in clinical practice.

METHODS:

This review is drawn from published literature, meeting abstracts and online resources.

RESULTS/CONCLUSION:

IGF1R blockade is generally well tolerated although it can induce hyperglycaemia. Single-agent activity has been documented in Ewing's sarcoma but not thus far in common solid tumours. Key issues include identification of factors that influence sensitivity to IGF1R blockade, and how most effectively to combine IGF1R inhibitors with other treatments.

PMID:
18410242
DOI:
10.1517/14728222.12.5.589
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center